Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
miércoles, octubre 21
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Anixa Biosciences Inc
ANIX
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$2.67
-0.015
-0.56%
Últ. Act.: Oct 21, 11:39 AM
$2.70
0.02
0.75%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Privacy Manager
Anixa Biosciences Financials
Anixa Biosciences (ANIX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Anixa Biosciences Q3 EPS $(0.08) Beats $(0.09) Estimate, Sales $0.00, Same YoY
Anixa Biosciences (NASDAQ:ANIX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 11.11 percent. This is a 14.29 percent decrease over losses of $(0.07) per share
Benzinga Newsdesk
PRO
Anixa Biosciences Q2 EPS $(0.07) Beats $(0.09) Estimate
Anixa Biosciences (NASDAQ:ANIX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.09) by 22.22 percent. This is a 22.22 percent increase over losses of $(0.09) per share from
Benzinga Newsdesk
PRO
Anixa Biosciences Q3 EPS $(0.07) Beats $(0.09) Estimate
Anixa Biosciences (NASDAQ:ANIX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.09) by 19.54 percent. This is a 30 percent increase over losses of $(0.10) per share from
Benzinga Newsdesk
PRO
Anixa Biosciences Highlights 2024 Achievements And 2025 Goals: Utilized $7M, Ended With $20M Cash, Presented Phase 1 Breast Cancer Vaccine Data With 70% Immune Response, Advanced Ovarian Cancer CAR-T Program, Preparing Phase 2 Study And Broader Cancer Vaccine Development
Benzinga Newsdesk
Recap: Anixa Biosciences Q1 Earnings
Benzinga Insights
Mid-Afternoon Market Update: Nasdaq Tumbles 150 Points; Knoll Shares Spike Higher
Toward the end of trading Monday, the Dow traded down 0.41% to 34,060.60 while the NASDAQ fell 1.08% to 13,900.17. The S&P also fell, dropping 0.59% to 4,160.89.
Lisa Levin
